Scarica l'app Stockscreener
18.68
0.69%
-0.13
Dopo l'orario di chiusura:
18.68
Precedente Chiudi:
$18.81
Aprire:
$18.97
Volume 24 ore:
800.78K
Relative Volume:
1.87
Capitalizzazione di mercato:
$1.02B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+2.30%
1M Prestazione:
+66.04%
6M Prestazione:
+58.84%
1 anno Prestazione:
-7.52%
Intervallo 1D:
$18.45
$19.24
Intervallo di 1 settimana:
$16.46
$19.71
Portata 52W:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Confronta BCAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.68 | 945.34M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara Therapeutics president Cohlhepp sells $226942 in shares - Investing.com
Bicara Therapeutics CEO Mazumdar sells $466k in shares - Investing.com India
Bicara Therapeutics CEO Mazumdar sells $466k in shares By Investing.com - Investing.com UK
Will Bicara Therapeutics Inc. stock see insider buying2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Is Bicara Therapeutics Inc. stock a buy before product launches2025 Short Interest & Verified Short-Term Trading Plans - newser.com
Using Python tools to backtest Bicara Therapeutics Inc. strategies2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Why Bicara Therapeutics Inc. stock is considered a top pickWeekly Profit Report & Safe Entry Point Identification - newser.com
Bicara Therapeutics Inc. stock chart pattern explainedTrade Entry Report & Fast Moving Trade Plans - newser.com
Is Bicara Therapeutics Inc. stock resilient to inflationJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
How Investors May Respond To Bicara Therapeutics (BCAX) FDA Breakthrough Therapy Nod for Lead Immunotherapy - Yahoo Finance
Bicara stock gains as H.C. Wainwright reiterates Buy rating on FDA breakthrough By Investing.com - Investing.com Australia
Bicara stock gains as H.C. Wainwright reiterates Buy rating on FDA breakthrough - Investing.com UK
Can Bicara Therapeutics Inc. recover in the next quarter2025 Buyback Activity & AI Enhanced Trading Alerts - newser.com
Key facts: Merck reports $63.62B revenue; Bicara gains FDA breakthrough - TradingView
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC - MarketScreener
Bicara stock jumps after FDA grants breakthrough therapy status By Investing.com - Investing.com Nigeria
Bicara stock jumps after FDA grants breakthrough therapy status - Investing.com
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation - MarketScreener
Bicara Therapeutics climbs after FDA's 'breakthrough' tag for cancer therapy - TradingView
Why Bicara Therapeutics Is Rising In Pre-market? - Nasdaq
FDA grants breakthrough therapy status to Bicara’s cancer drug - Investing.com
Bicara Therapeutics Announces Ficerafusp Alfa Granted - GlobeNewswire
Bicara Therapeutics Gets FDA Breakthrough for ficerafusp | BCAX Stock News - Stock Titan
How to build a custom watchlist for Bicara Therapeutics Inc.Weekly Trade Recap & Intraday High Probability Alerts - newser.com
Ivan Hyep Sells 6,415 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Insider David Raben Sells 22,000 Shares - MarketBeat
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares By Investing.com - Investing.com Australia
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 18,244 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $715,176.00 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 10,900 Shares - MarketBeat
Ivan Hyep Sells 6,514 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 5,627 Shares of Stock - MarketBeat
Risk adjusted return profile for Bicara Therapeutics Inc. analyzedJuly 2025 Selloffs & Breakout Confirmation Trade Signals - newser.com
Can Bicara Therapeutics Inc. stock resist sector downturnsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares By Investing.com - Investing.com Canada
Bicara therapeutics president Cohlhepp sells $911k in shares - Investing.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares - Investing.com
Bicara therapeutics president Cohlhepp sells $911k in shares By Investing.com - Investing.com UK
Day 8 of Gains Streak for Bicara Therapeutics Stock with 70% Return (vs. 4.3% YTD) [10/7/2025] - Trefis
4 Biotech Stocks Seeing Explosive Momentum GainsAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Statistical indicators supporting Bicara Therapeutics Inc.’s strengthGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
What drives Bicara Therapeutics Inc stock priceVWAP Trading Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Is Bicara Therapeutics Inc. stock reversal real or fakeJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Key metrics from Bicara Therapeutics Inc.’s quarterly dataQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Bicara Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Bicara Therapeutics files for mixed shelf offering of up to $400 millionSEC filing - MarketScreener
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Bicara Therapeutics Inc Azioni (BCAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire | Chief Executive Officer |
Oct 13 '25 |
Option Exercise |
3.79 |
11,445 |
43,374 |
321,337 |
| Mazumdar Claire | Chief Executive Officer |
Oct 15 '25 |
Sale |
18.84 |
13,289 |
250,391 |
309,892 |
| Mazumdar Claire | Chief Executive Officer |
Oct 13 '25 |
Sale |
18.92 |
11,445 |
216,545 |
309,892 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):